Femme et Homme
- | Pays :
- Russian Federation
- Canada
- Czech Republic
- Les 3 autres...
- | Organes : -
- | Spécialités : -
Extrait
The objective of the current study is to investigate the efficacy, safety and tolerability of several doses of BI 1356 BS (0.5, 2.5 and 5 mg daily) compared to placebo over 12 weeks of treatment in patients with Type 2 diabetes and insufficient glycemic control. In addition, there will be an open-label treatment arm with metformin for sensitivity measurement with this patient population. Population pharmacokinetics of BI 1356 BS will also be assessed in this study.
Critère d'inclusion
- Diabetes Mellitus, Type 2